BioArctic

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance

Fri, Dec 14, 2018 08:00 CET

Stockholm, Sweden, December 14, 2018 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic’s alpha-synuclein antibody portfolio for Parkinson’s disease and other potential indications to AbbVie. On November 2, 2018, BioArctic announced that the company had received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie and BioArctic. The exercise of the option was

There are no items matching the current filter

There are no more items matching the current filter

Back to top

About Us

BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance

Subscribe

Media

Share

About Us

BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Disease to AbbVie after receiving clearance

Subscribe

Media